Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May 18;11(5):1473.
doi: 10.3390/biomedicines11051473.

New Opportunities for Preoperative Diagnosis of Medullary Thyroid Carcinoma

Sergei A Lukyanov  1 , Sergei V Sergiyko  1 , Sergei E Titov  2   3   4 , Dmitry G Beltsevich  5 , Yulia A Veryaskina  6 , Vladimir E Vanushko  5 , Liliya S Urusova  5 , Alexander A Mikheenkov  5 , Evgeniya S Kozorezova  7 , Sergey L Vorobyov  7 , Ilya V Sleptsov  8
Affiliations

New Opportunities for Preoperative Diagnosis of Medullary Thyroid Carcinoma

Sergei A Lukyanov et al. Biomedicines. .

Abstract

The preoperative diagnostics of medullary thyroid carcinoma (MTC), including the measuring of the blood calcitonin level, has a number of limitations. Particular focus has recently been placed on the role of miRNAs in the development of various malignant tumors; a comparative analysis of accuracy of the existing methods for MTC diagnosis with a novel diagnosis method, evaluation of the miRNA-375 expression level, was performed in this study. The expression level of miRNA-375 in cytology samples from 555 patients with the known histological diagnosis, including 41 patients with confirmed postoperative diagnosis of MTC, was assessed. The diagnostic parameters of the basal calcitonin level, calcitonin in wash-out fluid from the FNAB needle, and miRNA-375 were compared. An assessment of the miRNA-375 expression level made it possible to detect all the MTC samples with a 100% accuracy among all the 555 cytology specimens, as well as in non-informative FNAB specimens, and specimens from the ipsilateral thyroid lobe. Parameters such as sensitivity, specificity, PPV, and NPV were 100%. The miRNA-375 level, unlike calcitonin, does not correlate with tumor volume, so it does not have the so-called "gray zone". An assessment of the miRNA-375 expression allows one to accurately distinguish MTC from other malignant and benign thyroid tumors.

Keywords: calcitonin; fine-needle aspiration samples; medullary thyroid carcinoma; miRNA-375; molecular testing.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Scheme for analyzing miRNA-375 and preoperative basal calcitonin in group 1 and 2 patients.
Figure 2
Figure 2
The relative expression level of miRNA-375 in goiters and thyroid/parathyroid tumors. The figure presents the median value, upper and lower quartiles, and non-outlier range, and outliers (circles). MTC, medullary thyroid carcinoma; PTC, papillary thyroid carcinoma; FTC, follicular thyroid carcinoma; OTC, oncocytic thyroid carcinoma; PTA, parathyroid adenoma; OA, oncocytic adenoma; and FA, follicular adenoma.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Cooper D.S., Doherty G.M., Haugen B.R., Kloos R.T., Lee S.L., Mandel S.J., Mazzaferri E.L., McIver B., Pacini F., Schlumberger M., et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167–1214. doi: 10.1089/thy.2009.0110. - DOI - PubMed
    1. Cancer of the Thyroid Invasive: Trends in SEER Incidence and U.S. Mortality Using the Joinpoint Regression Program, 1975–2011 (SEER) Stat Version 8.1.2 Rate Session. [(accessed on 13 December 2022)]; Available online: www.seer.cancer.gov.
    1. Jiménez C., Hu M.I., Gagel R.F. Management of medullary thyroid carcinoma. Endocrinol. Metab. Clin. N. Am. 2008;37:481–496. doi: 10.1016/j.ecl.2008.03.001. - DOI - PubMed
    1. Kebebew E., Ituarte P.H., Siperstein A.E., Duh Q.Y., Clark O.H. Medullary thyroid carcinoma: Clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer. 2000;88:1139–1148. doi: 10.1002/(SICI)1097-0142(20000301)88:5<1139::AID-CNCR26>3.0.CO;2-Z. - DOI - PubMed
    1. Pacini F., Castagna M.G., Cipri C., Schlumberger M. Medullary thyroid carcinoma. Clin. Oncol. 2010;22:475–485. doi: 10.1016/j.clon.2010.05.002. - DOI - PubMed

LinkOut - more resources